

## **AMENDMENTS TO THE SPECIFICATION:**

Please amend the specification as follows:

Page 10, replace the paragraph beginning on line 18, with the following amended paragraph:

Additionally, the compounds of the invention have inhibitory effects of lowering somatostatin-release ~~inhibiting effects~~, antidiabetic effects, urease inhibiting effects and the like and are useful as a somatostatin-release inhibitor, an antidiabetic drug, and an urease inhibitor.

Page 34, replace the paragraph beginning on line 10 through page 35, line 12 with the following amended paragraph:

The amine salts of carbostyryl derivative of the present invention have superior water solubility, and are especially useful for the preparation of formulations in the form of an aqueous solution, such as injections, ophthalmic solutions, oral solutions and the like; additionally keep the superior pharmacological effectiveness of the carbostyryl derivatives, such as antiulcer activity, activities for increasing endogenic-prostaglandin E2, extinction or inhibition of active oxygen, inhibition of IL-8 production, inhibition of granulocyte activation, inhibition of expression of granulocyte adhesion factor, inhibitory activity of lowering somatostatin-release ~~inhibitory activity~~, antidiabetic activity, urease inhibitory activity, and further an increasing of goblet cell in eye, an increasing of mucus in eye, an increasing of lacrimal fluid; and are useful as drugs for treating various diseases, especially as ophthalmic drops for treating various ophthalmopathy such as dry eye.

**REMARKS**

The amendments more accurately describe the effects of the claimed compounds.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: October 10, 2006

By: 

Arthur S. Garrett

Reg. No. 20,338

Tel: 202-408-4091

1191690\_1